Show Summary Details
Page of

Viral platforms for expression of tumor antigens in cancer immunotherapy 

Viral platforms for expression of tumor antigens in cancer immunotherapy
Viral platforms for expression of tumor antigens in cancer immunotherapy

Karishma Rajani

, Vanessa Alonso-Camino

, Nicolas Boisgerault

, and Richard Vile

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 10 December 2019

In the field of cancer virotherapy, many efforts are now focused on enhancing the immune response together with the direct lysis of tumor cells or inducement of apoptosis. One of the strategies that has emerged in this regard is the modification of viral vectors to encode for tumor-associated antigens (TAAs). The combination of viruses encoding TAAs with other approaches like the adoptive transfer of T cells, or the expression of multiple TAAs to target multiple epitopes, could also considerably improve the therapy and avoid tumor recurrence. This chapter focuses primarily on the recent advancements of adenovirus, poxvirus and vesicular stomatitis virus (VSV)-based preclinical studies, and clinical trials in tumour virotherapy.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.